Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 10/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.36 |
| ▸ | REN | P00797 | 2/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8233618 | 0.84 | CTSL (0.39) | NAAAIDO1AGXT | |
| SCHEMBL8240019 | 0.84 | CTSL (0.39) | NAAAIDO1AGXT | |
| SCHEMBL3051972 | 0.84 | CTSL (0.39) | NAAAIDO1AGXT | |
| SCHEMBL14734287 | 0.76 | NAAA (0.52) | NAAAIDO1AGXT | |
| SCHEMBL15883399 | 0.74 | NAAA (0.50) | NAAAIDO1AGXT | |
| SCHEMBL27034936 | 0.74 | NAAA (0.47) | NAAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14734276 | 0.72 | NAAA (0.48) | NAAAIDO1AGXTRENTACR1 | |
| SCHEMBL18615761 | 0.71 | NAAA (0.54) | NAAAIDO1AGXTREN | |
| SCHEMBL14734277 | 0.71 | NAAA (0.46) | NAAAIDO1AGXTSMN1; SMN2 | |
| SCHEMBL3049685 | 0.71 | NAAA (0.58) | NAAAIDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| EP-1960360-A1 | AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS | MERCK SHARP & DOHME LTD. (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007060484-A1 | AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060484-A1 | AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | GRIA1, GLRA1, GRIN1 | NAAA 2004/4885IDO1 243/4885AGXT 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.